NeuroOne Medical Technologies Corp. Hits New 52-Week Low at $3.22

NeuroOne Medical Technologies Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.22 as of June 11, 2026. This significant drop highlights ongoing challenges for the company, which has seen a notable decline in its financial performance metrics. Over the past year, NeuroOne has experienced a return of -4.78%, contrasting sharply with the S&P 500's performance of 22.78%. The company's net sales for the half-year period stood at USD 5.28 million, reflecting a decrease of 31.03%, while its net profit reported a loss of USD 3.74 million, a staggering decline of 195.48%. With a market capitalization of USD 37 million, NeuroOne's financial indicators reveal a negative return on equity of -116.32% and a debt-equity ratio of -0.54, suggesting a precarious financial position. The stock's price-to-book ratio is 5.81, indicating that the market may be valuing the company at a premium despite its current struggles. As the stock touches its 52-week low, it underscores the ongoing volatility and challenges faced by NeuroOne Medical Technologies Corp. in the competitive biotechnology landscape.